Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty


Contact us for more batch information
Select Batch


Catalog No. T15095Cas No. 4914-30-1
Dehydroemetine is an effective antigenic insecticide, which is a synthetic analogue of Emetine dihydrochloride. It can be used to prevent and treat amoeba infections and diseases. It has the effect of treating leishmania infection with skin damage and resistance to metronidazole amoebiosis.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePrice/USDAvailabilityQuantity
1 mg$129In Stock
5 mg$322In Stock
10 mg$487In Stock
25 mg$750In Stock
50 mg$987In Stock
100 mg$1,350In Stock
500 mg Inquiry In Stock
1 mL x 10 mM (in DMSO)$355In Stock
Bulk & Custom
Add to Cart
View More

Related Compound Libraries of "Dehydroemetine"

Product Introduction

Dehydroemetine is an effective antigenic insecticide, which is a synthetic analogue of Emetine dihydrochloride. It can be used to prevent and treat amoeba infections and diseases. It has the effect of treating leishmania infection with skin damage and resistance to metronidazole amoebiosis.
In vivo
The mechanism of the inhibitory effect of Dehydroemetine on the heart was investigated using (a) the spontaneously contracting isolated guinea-pig atrial preparation and (b), the electrically driven left atrial preparation. Dehydroemetine decreased the rate and amplitude of contraction of spontaneously contracting atria. Increasing the calcium concentration of the bath fluid to 28.2 mM abolished the effect of Dehydroemetine on the amplitude of contraction while the effect on the rate persisted. Pretreatment with Dehydroemetine increased the capacity of ouabain to induce arrhythmias in spontaneously contracting atria. Similarly, pretreatment with ouabain augmented the inhibitory effect of Dehydroemetine on spontaneous atrial activity. In the electrically driven left atrial preparation, Dehydroemetine caused a decrease in contractile strength which was opposed by ouabain and by increased calcium concentration of the bath fluid. The effect of Dehydroemetine on spontaneously contracting and on electrically driven atria was mimicked by adding excess potassium to the bath fluid. It was concluded that the effects of Dehydroemetine on rate and contractility are, to a large extent, independent of one another. The effect on spontaneous rate is consistent with alteration of the potassium permeability of the myocardial cell membrane while the effect on contractility appears to be due to a decrease in the uptake of calcium from the medium by the myocardial cell.[1]
Chemical Properties
Molecular Weight478.62
Cas No.4914-30-1
Storage & Solubility Information
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 45.0 mg/mL (94.0 mM)
Solution Preparation Table
1 mM2.0893 mL10.4467 mL20.8934 mL104.4670 mL
5 mM0.4179 mL2.0893 mL4.1787 mL20.8934 mL
10 mM0.2089 mL1.0447 mL2.0893 mL10.4467 mL
20 mM0.1045 mL0.5223 mL1.0447 mL5.2234 mL
50 mM0.0418 mL0.2089 mL0.4179 mL2.0893 mL


  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg,each TargetMol | Animal experiments animal weighs 20 g, and the dosage volume is 100 μL. A total of TargetMol | Animal experiments 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL.
Mother liquor preparation method: 2 mg of drug dissolved in 50 μLDMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μLDMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μLTween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify.
1 Enter information below:
2 Enter the in vivo formulation:
%Tween 80

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.